1. Home
  2. INDP vs SNOA Comparison

INDP vs SNOA Comparison

Compare INDP & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • SNOA
  • Stock Information
  • Founded
  • INDP 2000
  • SNOA 1999
  • Country
  • INDP United States
  • SNOA United States
  • Employees
  • INDP N/A
  • SNOA N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • SNOA Biotechnology: Pharmaceutical Preparations
  • Sector
  • INDP Health Care
  • SNOA Health Care
  • Exchange
  • INDP Nasdaq
  • SNOA Nasdaq
  • Market Cap
  • INDP 7.4M
  • SNOA 6.4M
  • IPO Year
  • INDP N/A
  • SNOA 2007
  • Fundamental
  • Price
  • INDP $0.35
  • SNOA $3.37
  • Analyst Decision
  • INDP Strong Buy
  • SNOA
  • Analyst Count
  • INDP 2
  • SNOA 0
  • Target Price
  • INDP $8.50
  • SNOA N/A
  • AVG Volume (30 Days)
  • INDP 757.0K
  • SNOA 62.5K
  • Earning Date
  • INDP 05-14-2025
  • SNOA 06-16-2025
  • Dividend Yield
  • INDP N/A
  • SNOA N/A
  • EPS Growth
  • INDP N/A
  • SNOA N/A
  • EPS
  • INDP N/A
  • SNOA N/A
  • Revenue
  • INDP N/A
  • SNOA $13,973,000.00
  • Revenue This Year
  • INDP N/A
  • SNOA $23.89
  • Revenue Next Year
  • INDP N/A
  • SNOA $25.45
  • P/E Ratio
  • INDP N/A
  • SNOA N/A
  • Revenue Growth
  • INDP N/A
  • SNOA 13.51
  • 52 Week Low
  • INDP $0.31
  • SNOA $1.75
  • 52 Week High
  • INDP $2.89
  • SNOA $9.37
  • Technical
  • Relative Strength Index (RSI)
  • INDP 39.89
  • SNOA 53.99
  • Support Level
  • INDP $0.31
  • SNOA $3.05
  • Resistance Level
  • INDP $0.37
  • SNOA $3.60
  • Average True Range (ATR)
  • INDP 0.04
  • SNOA 0.20
  • MACD
  • INDP 0.00
  • SNOA 0.00
  • Stochastic Oscillator
  • INDP 26.55
  • SNOA 58.18

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: